Arstat Pharmaceuticals is a pharmaceutical company that develops innovative medical devices and products for women’s health care. The company focuses on areas of women’s health that have a significant unmet medical need. Arstat’s products have proven efficacy and safety, and the company’s high-value portfolio is protected by several U.S. patents.
Revolutionary Women’s Health Products
Arstat Pharmaceuticals has developed products that focus on major areas of unmet medical needs in women’s health. Their products include contraception for overweight and obese women, uterine fibroids and endometriosis, and painful and heavy menstrual periods. The pipeline includes four drug candidates with proven efficacy and safety. Two products are Phase III-ready, and two other products are ready for Phase IIb. The company is targeting a global market of over 800 million women, with significant European and worldwide sales.
Nuvocept – A Game-Changing Contraceptive
Arstat’s most valuable asset is Nuvocept, the first and only oral contraceptive designed explicitly for overweight and obese women. The FDA has endorsed an unprecedented clinical program and a potentially unique label. Nuvocept is expected to dominate a multi-billion-dollar segment of the U.S. contraceptive market.
Expertise in Women’s Health
Arstat’s Founder and CEO, Arkady Rubin, has over 30 years of industry experience, including working with J&J and Pfizer. Rubin is the co-inventor of Ortho Tri-Cyclen Lo, the best-selling oral contraceptive in the U.S. with peak sales exceeding $500 million per year. The Arstat team has extensive experience in drug development, clinical trials, and regulatory approval.
Fundraising for Future Growth
Arstat is currently raising a seed financing round to hire key executives, assemble a top-notch Board of Directors, and prepare for a $50.0 million public offering one year later. The company’s goal is to advance its Phase III candidates through NDA filing, FDA approval, and sale or out-licensing in 3 – 3.5 years from the initial financing round as well as complete Phase IIb studies for its remaining candidates. Conservative estimates of the fair value of Arstat’s product portfolio at the time of the public offering are between $500 – $800 million.
Arstat Pharmaceuticals is poised to revolutionize the women’s health market with its innovative products and its team’s expertise in drug development, clinical trials, and regulatory approval. The company’s focus on major areas of unmet medical needs in women’s health, including contraception for overweight and obese women, will have a significant impact on the market. Arstat’s Nuvocept, the first and only oral contraceptive designed explicitly for overweight and obese women, is expected to dominate a multi-billion-dollar segment of the U.S. contraceptive market. Arstat’s seed financing round and planned public offering will enable the company to achieve its goal of advancing its Phase III candidates through NDA filing, FDA approval, and sale or out-licensing.
Ready to amplify your reach and engage with the most dynamic community in the venture world? Consider sponsoring an article with us. Learn more about our promotional opportunities and sponsored articles here.
Your story could be the next big hit on US Venture News!